Case 1

• A 65 year-old right handed woman with a history of HTN and DM presented to the ED after the sudden onset of right sided weakness.
• Exam shows mild expressive aphasia, R face and arm weakness as well as L gaze deviation.
• She was last seen normal at 1 p.m., and it is now 2:45 pm

UCSF “Stroke Protocol” CT

• Obtained at UCSF in suspected acute stroke and TIA patients <12 hours from onset
1. Non-contrast CT of the head
2. CT Angiography from aortic arch to the top of the head
3. CT Perfusion study
4. Post-contrast CT of the head

What treatment should this patient likely receive?

A. IV t-PA alone
B. IV t-PA followed by embolectomy
C. Embolectomy alone
D. IV heparin
E. Antiplatelets
The 2016 Acute Stroke Timeline

- Time of onset = last time seen normal
  
  0-4.5 Hours  IV-tPA
  
  0-6* Hours  Mechanical Embolectomy
  
  Greater than 6* hours  Anticoagulants or Antiplatelets

*=Basilar occlusions to 12 hours

Intravenous t-PA: Proven, Approved

- Pivotal IV t-PA NINDS trial (0-3 hours)
  
  - 30% increase in minimal or no disability at 90 days, not the Lazarus effect
  
  - Symptomatic hemorrhage risk increased 0.6 to 6.4%, half were serious and fatal
  
  - No change in mortality
  
  - Multiple recent studies confirm this result in diverse settings
  
  - THE EARLIER THE BETTER!!

Speed Matters: Time is Brain

- Examination of the Get With the Guideline Registry in the U.S. over the last decade
  
  - 1400 hospitals, nearly 59,000 patients
  
  - Mean time to treatment was 144 minutes
    - Earlier on weekdays, more severe stroke, arrival in ambulance
  
  - For every 15 min earlier administration...
    - Significantly lower in-house mortality
    - Significantly lower rates of ICH
    - Significantly more independent ambulation at d/c
    - Significantly higher rate of d/c to home

Intravenous t-PA: 3-4.5 hours

- ECASS III trial (9/08)
  
  - 821 pts randomized to t-PA vs placebo
  
  - Median time: 3h 59min
  
  - Favorable outcome: 52% vs 45%, p=0.04
  
  - Symptomatic ICH: 2.4% vs 0.2%, p=0.008
  
  - No mortality difference


Intravenous t-PA: Broad Success

The 2015 Endovascular Revolution

- Five major positive trials of endovascular therapy all published in 2015 in NEJM
- Trial design somewhat differed, but common to each:
  - 1. Used newer-generation devices
  - 2. Selected patients who were eligible via CTA (less commonly perfusion)
  - 3. IV t-PA in those who were eligible followed by embolectomy
  - 4. At least 6 hour time window

90-day functional outcomes significantly improved with endovascular treatment (nearly doubled odds of good outcome)
- No increased risk of hemorrhage
- First time a mortality benefit has been shown in an acute stroke trial (1 trial)
- First time perfusion selection has been shown to be beneficial (likely not ready for widespread adaptation yet)

What do we do given this data?

- 1. All patients eligible for IV t-PA should receive it (quickly)
- 2. Patients within 6 hours (for now) should receive a CTA to look for a large vessel occlusion (LVO)
- 3. If LVO present, endovascular therapy should occur, even following IV t-PA
- Fundamental shift in hospital protocols including transfer protocols
Case 2

• A 76 year-old man with a history of smoking presents with 3 days of R hand weakness
• Examination shows a R pronator drift and slowed movements of the R hand
• The patient takes aspirin 81mg daily as well as lisinopril

Which of the following is not part of the standard embolic stroke workup?

A. Echocardiogram  
B. Extended cardiac telemetry  
C. Lipid panel  
D. B12, TSH, RPR, ESR  
E. Carotid evaluation

Standard Large-Vessel Stroke Workup

• Cardioembolic: afib, clot in heart, paradoxical embolus  
  • 1. Telemetry  
  • 2. TEE with bubble study  
• Aortic Arch  
  • 2. TEE with bubble study  
• Carotids  
  • 3. Carotid Imaging (CTA, US, MRA, angio)  
• Intracranial Vessels  
  • 4. Intracranial Imaging (CTA, MRA, angio)  

And evaluate stroke risk factors

TEE vs. TTE

• 231 consecutive TIA and stroke patients of unknown etiology underwent TTE and TEE  
• 127 found to have a cardiac cause of emboli, 90 of which (71 percent) only seen on TEE  
• TEE superior to TTE for: LA appendage, R to L shunt, examination of aortic arch  
• Recent study: TEE found additional findings in 52% and changed management in 10%

Atrial Fibrillation Detection

- EKG
- 48 Hours of Telemetry
- Long-term cardiac event monitor (>21d)
  - 15-20% of patients with cryptogenic stroke otherwise unexplained had afib detected
  - Clearly changes management
  - Probably cost effective


Approach to Stroke Treatment

Acute Stroke Therapy?

- No
  - Anticoagulants?
    - No
      - Antiplatelets
  - Yes
    - No

Shrinking Indications for Anticoagulation in Stroke

1. Atrial Fibrillation
2. Some other cardioembolic sources
   - Thrombus seen in heart
     - LVEF<35 - WARCEF 2012
     - PFO with associated Atrial Septal Aneurysm - CADISS 2015
3. Vertebral or Carotid dissection
4. Rare hypercoagulable states: APLS
Heparin in Acute Stroke

- Study examined the largest trials of heparin, heparinoids, LMWH in acute stroke
- Could find no benefit even in those patients with highest risk of recurrent ischemia and lowest risk of hemorrhage
- Considering use of heparin for “selected patients” therefore seems unwise


The Excitement Over the Demise of Warfarin

- Oral direct thrombin and Xa inhibitors will hopefully lead to more patients with afib being anticoagulated
- Stroke-specific concerns
  - Little acute data for secondary prevention
  - Contraindications to tPA
  - Reversal

Case 3

- A 70 year-old man with a history of DM, smoking presents 10 hours after the onset of slurred speech and right arm and leg weakness.
- The patient is on ASA 81mg daily

Stroke workup is unrevealing. 
your Treatment?

A. Increase ASA to 325mg daily
B. Add Plavix to ASA
C. Stop ASA, start Plavix
D. Stop ASA, start Aggrenox
E. Anticoagulate
Approach to Stroke Treatment

Acute Stroke Therapy?
- No

Anticoagulants?
- No

Antiplatelets

Antiplatelet Options

- 1. ASA
  - 50mg to 1.5g equal efficacy long-term
- 2. Aggrenox
  - 25mg ASA/200mg ER Dipyridamole
- 3. Clopidogrel (Plavix)
  - Multiple secondary prevention studies (CHARISMA, SPS3) show no long-term benefit in combination with ASA

PRoFESS Trial

- Randomized, double-blind trial of Aggrenox versus Plavix in over 20,000 patients with ischemic stroke
- Recurrent 4-year event rates basically identical between the two medications
  - HR for Aggrenox 1.01 (95% CI, 0.92-1.11)
  - Composite of stroke, MI, vascular death: 13.1% in each
  - Major hemorrhagic events higher in Aggrenox group

A Future Option?  

Clopidogrel + ASA: Ever A Winning Combination?

- CHANCE trial
  - 5170 TIA or Minor Stroke patients assigned to daily ASA + Placebo versus daily ASA + Clopidogrel following 300mg load
  - Primary outcome was stroke at 90 days
    - NNT=29 to prevent 1 stroke
    - Similar safety endpoints
  - Generalizability?
    - Await POINT trial results
  - 2016: Not all pts benefit
    - CYP2C19 loss of function

Other Acute Stroke Management
- Statins for (almost) all
  - SPARCL (NEJM 8/06), 80mg atorvastatin in stroke and TIA if LDL>100
- Tight Glucose and Fever control
- Enoxaparin for DVT prophylaxis
  - PREVAIL trial (Lancet 2007)
  - CLOTS trial 1 (Lancet 2009): Compression Stockings

Permissive Hypertension
- National Guidelines
  - To at least 220/120
  - After IV tPA: less than 185 systolic for 24 hours
- We typically stop all meds except half-dose β-blockers
Permissive Hypertension

- When to stop remains controversial
- Situations where more important
  - Large Vessel Occlusion
  - Fluctuating Symptoms
- We begin a medicine before discharge (~72h) and aim for normotension over a matter of weeks
  - Choose thiazides and ACEI first

Case 4

- A 73 year-old woman with HTN comes to the ED after a 5 minute episode of right arm weakness that has since resolved.
- Exam is normal except blood pressure is elevated at 176/97

Other than TIA, what is the most common neurologic diagnosis here?

A. Conversion disorder
B. Migraine
C. Focal Seizure
D. UTI
E. Cervical spine lesion

TIA versus Stroke

- Up to 30-50% of TIA have infarct on MRI
- Conceptually the same disorder
  - Same workup, same treatment
- Pendulum swing
  - Pre-2001: Much more aggressive with stroke
  - 2002-2007: TIA and stroke equally aggressive
  - 2008-present: A more aggressive approach with TIA outside of the acute treatment window
Risk of Future Stroke with TIA: AB
c2 Score

• 7-day risk overall 8.6-10.5 percent
• Age
  – >60 =1 point
• Blood Pressure
  – SBP>140 or DBP>90 =1 point
• Clinical Features
  – Unilateral weakness =2 points
  – Speech disturbance without weakness =1 point
• Duration
  – >60 minutes =2 points
  – 10-59 minutes =1 point
• Diabetes=1 point


Aggressive Therapy for TIA

• 1. SOS-TIA trial
  – 1085 patients with TIA admitted to a 24-hour center
  – All treated with standard therapy
  – 74 percent discharged on same day, stroke risk reduced 80 percent from
ABCD2 prediction
• 2. EXPRESS study
  – 80 percent reduction in risk with urgent TIA clinic visit versus usual primary care visit in 1278 patients


TIA Aggressive Therapy:
A Modern Look

• 2009-2011 TIA registry of nearly 5000 patients
• Population at baseline was high risk as with historical cohorts
• 78% saw a stroke specialist within 24 hours
  – Hospitals not mentioned in this European study
• 1-year stroke rate was 5.1%
• Rates at 2d, 7d, 30d, 90d, 1y were all less than half of that in historical cohorts


When to Fix the Carotid?

• NASCET in early 1990s
  – Benefit of endarterectomy in patients with symptoms ipsilateral to 70-99% stenosis
    • Comparison: best medical management at the time
  – 50-69% symptomatic stenosis revascularization has limited benefit, especially in women
• In stroke management don’t miss carotid disease or atrial fibrillation

How to Fix the Carotid?

• Stenting vs. CEA: CREST Trial
• 4-year study of 1321 symptomatic and 1181 asymptomatic patients randomized to CEA vs. carotid stenting
• Combined endpoint of stroke, MI, death not significantly different
  – More strokes in first 90 days in stenting group, more MIs in surgical group
  – After 90 days, similar endpoints


Result confirmed over 5 years in a 2015 trial